Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.

The efficacy of nivolumab did not deteriorate and the tolerability was also maintained even in later-line therapy. However, a tendency of longer OS and a higher chance of subsequent therapy after nivolumab failure were observed with nivolumab as second-line therapy.